Evelo Biosciences, Inc.
Evelo Biosciences, Inc.（EVLO）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · EVLO · 截至 2026年6月9日
活动摘要
买入笔数
3
P-Purchase only
卖出笔数
18
近12个月
买卖比
0.17
Buy/Sell (by trades)
整体情绪
Evelo Biosciences, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
EVLO 季度内部人买卖趋势
EVLO 内幕交易卖出 · EVLO 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
EVLO 高管卖出股份 · EVLO 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Nov 7, 2023 | Bodmer Mark CSO, President of R&D | Option | 6,625 | — | Form 4 |
| Nov 8, 2023 | Bodmer Mark CSO, President of R&D | Sale | 3,163 | $1K | Form 4 |
| Nov 7, 2023 | McHale Duncan Chief Medical Officer | Option | 6,500 | — | Form 4 |
| Nov 8, 2023 | McHale Duncan Chief Medical Officer | Sale | 3,103 | $1K | Form 4 |
| Nov 7, 2023 | GILL SIMBA President & CEO · Director | Option | 1,172 | — | Form 4 |
| Nov 8, 2023 | GILL SIMBA President & CEO · Director | Sale | 172 | $57 | Form 4 |
| Nov 7, 2023 | Thorell Marella CFO | Option | 6,500 | — | Form 4 |
| Nov 8, 2023 | Thorell Marella CFO | Sale | 1,811 | $598 | Form 4 |
| Nov 1, 2023 | Bodmer Mark CSO, President of R&D | Option | 12,500 | — | Form 4 |
| Nov 2, 2023 | Bodmer Mark CSO, President of R&D | Sale | 6,854 | $2K | Form 4 |
| Nov 1, 2023 | McHale Duncan Chief Medical Officer | Option | 12,500 | — | Form 4 |
| Nov 2, 2023 | McHale Duncan Chief Medical Officer | Sale | 6,854 | $2K | Form 4 |
| Nov 1, 2023 | Thorell Marella CFO | Option | 12,500 | — | Form 4 |
| Nov 2, 2023 | Thorell Marella CFO | Sale | 3,999 | $1K | Form 4 |
| Sep 27, 2023 | GILL SIMBA President & CEO · Director | Option | 15,000 | — | Form 4 |
| Sep 28, 2023 | GILL SIMBA President & CEO · Director | Sale | 1,996 | $8K | Form 4 |
| Aug 7, 2023 | Bodmer Mark CSO, President of R&D | Option | 6,625 | — | Form 4 |
| Aug 8, 2023 | Bodmer Mark CSO, President of R&D | Sale | 3,128 | $30K | Form 4 |
| Aug 7, 2023 | GILL SIMBA President & CEO · Director | Option | 1,171 | — | Form 4 |
| Aug 8, 2023 | GILL SIMBA President & CEO · Director | Sale | 342 | $3K | Form 4 |
| Aug 7, 2023 | McHale Duncan Chief Medical Officer | Option | 6,500 | — | Form 4 |
| Aug 8, 2023 | McHale Duncan Chief Medical Officer | Sale | 3,434 | $33K | Form 4 |
| Aug 7, 2023 | Thorell Marella CFO | Option | 6,500 | — | Form 4 |
| Aug 8, 2023 | Thorell Marella CFO | Sale | 2,004 | $19K | Form 4 |
| Jul 11, 2023 | Flagship Ventures Fund IV General Partner LLC 10 percent owner | Purchase | 3,246,753 | $7.50M⚡ | Form 4 |
Flagship Ventures Fund IV General Partner LLC
10 percent owner
日期
Jul 11
股数
3,246,753
均价
$2.31
总金额
$7.50M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 EVLO 内幕交易
EVLO 内幕交易
Evelo Biosciences, Inc.（EVLO）内幕交易数据来源于公司内部人（包括EVLO）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。EVLO内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Evelo Biosciences, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
EVLO 内幕交易 · 5个问题Evelo Biosciences, Inc.（EVLO）的内部人包括高管和董事，如EVLO等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026